Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Loss of heterozygosity occurs frequently on the short arm of chromosome 8 in many neoplasms, including colorectal and ovarian cancer. Monochromosome transfer experiments into colorectal tumour cell lines have provided functional evidence for a
tumour suppressor
gene located at 8p22-23. One of the genes from this region that is expressed by our suppressed hybrids is a candidate
tumour suppressor
gene,
DLC1
(deleted in liver cancer), which has homology to rat RhoGAP. We have delineated the structure of the
DLC1
gene and used single-stranded conformation polymorphism analysis (SSCP) to look for sequence variants in 126 colorectal and 33 ovarian primary tumours and cell lines. One exonic missense mutation and three intronic insertions/deletions were identified in primary colorectal tumours, as well as many polymorphisms present in germline DNAs. The rarity of exonic missense mutations, and the absence of protein-truncating mutations, indicates that
DLC1
is not the target of 8p LOH in colorectal or ovarian tumours. The delineation of the gene structure allows mutation analysis of
DLC1
in other tumour types for which it remains a candidate
tumour suppressor
gene based on its location and homology to rhoGAP.
...
PMID:Sequence variants of DLC1 in colorectal and ovarian tumours. 1064 92
Allelic imbalance on chromosome arm 8p is common in head and neck squamous cell carcinoma (HNSCC).
DLC1
, a
tumour suppressor
gene inactivated in liver carcinogenesis and encoding a Rho GTPase activating protein (RhoGAP) maps to one of the deleted regions (8p21.3-22). In order to determine whether inactivation of
DLC1
is involved in HNSCC, we have screened tumour cell lines for
DLC1
mutations and expression. Pathological mutations were not identified in any of the 17 cell lines tested. Seven polymorphisms were identified; 13 of the 17 of cell lines were homozygous for all seven polymorphisms compared to only 2 of 17 controls suggesting a loss of heterozygosity in a majority of the cell lines.
DLC1
expression was observed in all 11 HNSCC cell lines tested, thus excluding the possibility of transcriptional silencing of
DLC1
by promoter hypermethylation. Overall, our data suggest that hemizygous deletions of the
DLC1
locus are frequent in HNSCCs but this gene is unlikely to be primary target for inactivation on this chromosomal arm.
...
PMID:DLC1 is unlikely to be a primary target for deletions on chromosome arm 8p22 in head and neck squamous cell carcinoma. 1515 23
Hypermethylation of CpG islands within gene promoters is one of various mechanisms of gene silencing involved in the pathogenesis of human cancer. By using methylation-specific polymerase chain reaction we explored aberrant promoter methylation of five
tumour suppressor
genes in 29 patients with chronic lymphocytic leukaemia. Aberrant methylation of
DLC1
, SHP1, p15 and p16 occurred, respectively, in 89.7 %, 70 %, 62.1 % and 31 % of patients at diagnosis. Lamin A/C was unmethylated in all the samples. Hypermethylation of at least one gene was detected in 96.6 % of patients. Concurrent methylation of two or more genes correlated with Rai stage at diagnosis.
...
PMID:Advanced rai stage in patients with chronic lymphocytic leukaemia correlates with simultaneous hypermethylation of plural tumour suppressor genes. 2097 48
RhoGAP proteins control the precise regulation of the ubiquitous small RhoGTPases. The Drosophila Crossveinless-c (Cv-c) RhoGAP is homologous to the human
tumour suppressor
proteins Deleted in Liver Cancer 1-3 (DLC1-3) sharing an identical arrangement of SAM, GAP and START protein domains. Here we analyse in Drosophila the requirement of each Cv-c domain to its function and cellular localization. We show that the basolateral membrane association of Cv-c is key for its epithelial function and find that the GAP domain targeted to the membrane can perform its RhoGAP activity independently of the rest of the protein, implying the SAM and START domains perform regulatory roles. We propose the SAM domain has a repressor effect over the GAP domain that is counteracted by the START domain, while the basolateral localization is mediated by a central, non-conserved Cv-c region. We find that DLC3 and Cv-c expression in the Drosophila ectoderm cause identical effects. In contrast,
DLC1
is inactive but becomes functional if the central non-conserved
DLC1
domain is substituted for that of Cv-c. Thus, these RhoGAP proteins are functionally equivalent, opening up the use of Drosophila as an in vivo model to analyse pharmacologically and genetically the human DLC proteins.
...
PMID:Functional analysis of the Drosophila RhoGAP Cv-c protein and its equivalence to the human DLC3 and DLC1 proteins. 3263 22